ATE280947T1 - Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung - Google Patents

Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung

Info

Publication number
ATE280947T1
ATE280947T1 AT98939404T AT98939404T ATE280947T1 AT E280947 T1 ATE280947 T1 AT E280947T1 AT 98939404 T AT98939404 T AT 98939404T AT 98939404 T AT98939404 T AT 98939404T AT E280947 T1 ATE280947 T1 AT E280947T1
Authority
AT
Austria
Prior art keywords
hiv
application
functional fragments
vpr protein
disclosed
Prior art date
Application number
AT98939404T
Other languages
English (en)
Inventor
Sundarasamy Mahalingam
Velpandi Ayyavoo
Mamata Patel
Thomas Kieber-Emmons
David B Weiner
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE280947T1 publication Critical patent/ATE280947T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT98939404T 1997-08-14 1998-08-14 Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung ATE280947T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5575497P 1997-08-14 1997-08-14
PCT/US1998/016890 WO1999009412A1 (en) 1997-08-14 1998-08-14 Functional fragments of hiv-1 vpr protein and methods of using the same

Publications (1)

Publication Number Publication Date
ATE280947T1 true ATE280947T1 (de) 2004-11-15

Family

ID=21999943

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98939404T ATE280947T1 (de) 1997-08-14 1998-08-14 Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung

Country Status (8)

Country Link
US (1) US6087486A (de)
EP (1) EP1012603B1 (de)
AT (1) ATE280947T1 (de)
AU (1) AU753031B2 (de)
CA (1) CA2301295A1 (de)
DE (1) DE69827284T2 (de)
ES (1) ES2232956T3 (de)
WO (1) WO1999009412A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360347C (en) * 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
JP4776075B2 (ja) * 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6984486B1 (en) 1999-02-19 2006-01-10 J. David Gladstone Institutes Synthetic peptide of regulatory virus protein R (VPR) of human immunodeficiency virus type 1 (HIV-1) and the utilization thereof
WO2001074163A1 (en) * 2000-03-31 2001-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using hiv vpr
AU2006203114B2 (en) * 2000-03-31 2008-12-04 The Trustees Of The University Of Pennsylvania Compositions and methods of using HIV Vpr
US6664040B2 (en) 2000-05-23 2003-12-16 The Regents Of The University Of California Compositions and methods for delivery of a molecule into a cell
WO2002100317A2 (en) 2001-05-25 2002-12-19 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2003004657A1 (en) * 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
FR2827866B1 (fr) * 2001-07-27 2004-12-10 Pasteur Institut Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
WO2003020876A2 (en) * 2001-08-31 2003-03-13 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US20060051764A1 (en) * 2002-10-21 2006-03-09 Michael Mandola Thymidylate synthase polymorphisms for use in screening for cancer susceptibility
WO2005103654A2 (fr) * 2004-04-09 2005-11-03 Bioalliance Pharma Methode d’identification de composes actifs sur la replication du virus hiv.
WO2007052689A1 (ja) * 2005-11-04 2007-05-10 Japan As Represented By President Of National Cardiovascular Center 遺伝子導入剤及び遺伝子ベクター
WO2008108505A1 (ja) * 2007-03-07 2008-09-12 Japan As Represented By President Of International Medical Center Of Japan 新規核内移行ペプチド

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001230A (en) * 1988-02-18 1991-03-19 Schering Corporation T cell activation markers
IL108707A (en) * 1993-02-19 1999-06-20 Weiner David B Pharmaceutical compositions and diagnostic kits containing RPH protein or RPV-binding proteins
JPH09511395A (ja) * 1994-03-25 1997-11-18 バイオモレキュラー リサーチ インスティテュート リミティド ＨＩＶ の Ｖｐｒ及び Ｖｐｘ蛋白質
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
US5639598A (en) * 1994-05-19 1997-06-17 The Trustees Of The University Of Pennsylvania Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
US5763190A (en) * 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
CA2230925C (en) * 1995-04-14 2010-10-12 University Of Alabama Research Foundation Fusion protein delivery system and uses thereof

Also Published As

Publication number Publication date
DE69827284T2 (de) 2005-12-01
US6087486A (en) 2000-07-11
EP1012603A1 (de) 2000-06-28
WO1999009412A1 (en) 1999-02-25
CA2301295A1 (en) 1999-02-25
EP1012603B1 (de) 2004-10-27
DE69827284D1 (de) 2004-12-02
ES2232956T3 (es) 2005-06-01
EP1012603A4 (de) 2001-04-25
AU8783898A (en) 1999-03-08
AU753031B2 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
DE69827284D1 (de) Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung
FR19C1020I1 (fr) Nouvelles molecules b7-4 et leurs utilisations
EP0804609A4 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
DE69835143D1 (de) Selektion von proteinen mittels rns-protein fusionen
TR199801794T2 (xx) �nsan bikunini.
ATE397752T1 (de) Verfahren und verwendung von anordungen von proteinfixierungsmitteln
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
NO944245L (no) Rekombinante DNA-molekyler som koder for aminopeptidase-enzymer og deres anvendelse ved fremstilling av vaksiner mot helmintinfeksjoner
EE200000152A (et) Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
ATE305037T1 (de) Peptide, die fähig sind die sh3-domäne des gap- proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung
MXPA04004561A (es) Distribuidor de aire para sistema de biolixiviacion.
DE60140559D1 (de) 32144, eine humane fettsäureamid-hydrolase und deren verwendungen
DE69734586D1 (de) Retinoid-metabolisierendes protein
DE60139113D1 (de) 18477, eine menschliche proteinkinase und deren verwendung
EA200401390A1 (ru) N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения
WO2001092493A3 (en) 21956 and 25856, human aminopeptidases and uses thereof
EP0809103A3 (de) Stabile Denaturierungsmittel für elektroforetische Techniken und dafür geeignete Verfahren
DE60142356D1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
DE69733948D1 (de) In vivo herstellung von replicativen molekülen
DE60137222D1 (de) Humanes trp-ähnliches kalziumkanalprotein-2 tlcc-2
AP9901510A0 (en) Polypeptides comprising gax protein domains, involved in repressing transcription and or interacting with other proteins corresponding nucleic acids andtheir use.
AR009416A1 (es) Nuevos genes que codifican proeinas de telomerasa
BR9810643A (pt) Genes e proteìnas de telomerase de vertebrado, eutilização dos mesmos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1012603

Country of ref document: EP

REN Ceased due to non-payment of the annual fee